Invenomic Capital Management’s Global Payments GPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$61.5M Buy
914,505
+117,009
+15% +$8.63M 2.82% 3
2025
Q4
$61.7M Buy
797,496
+116,402
+17% +$9.37M 2.87% 2
2025
Q3
$56.6M Buy
681,094
+68,071
+11% +$5.73M 2.74% 2
2025
Q2
$49.1M Buy
613,023
+109,057
+22% +$8.63M 2.79% 1
2025
Q1
$49.3M Sell
503,966
-31,488
-6% -$3.29M 2.49% 3
2024
Q4
$60M Sell
535,454
-146,803
-22% -$16.1M 2.86% 3
2024
Q3
$69.9M Buy
682,257
+205,851
+43% +$21.4M 3.84% 1
2024
Q2
$46.1M Buy
476,406
+268,780
+129% +$29.6M 2.24% 4
2024
Q1
$27.8M Buy
207,626
+61,801
+42% +$8.17M 1.48% 19
2023
Q4
$18.5M Sell
145,825
-105,746
-42% -$12.2M 0.84% 37
2023
Q3
$29M Buy
251,571
+6,679
+3% +$795K 1.22% 24
2023
Q2
$24.1M Buy
244,892
+43,022
+21% +$4.42M 1.22% 25
2023
Q1
$21.2M Buy
+201,870
New +$21.9M 1.2% 30

Other funds holding GPN

Invenomic Capital Management's GPN Position: Q1 2026 in Review

Invenomic Capital Management increased its Global Payments (GPN) stake by 15% in Q1 2026, buying an estimated $8.63M and bringing the position to 914,505 shares worth $61.5M. The position accounts for 2.82% of the portfolio, ranked #3.

Invenomic Capital Management first reported a position in GPN in Q1 2023 and has held it in 13 quarters since. The position peaked at $69.9M in Q3 2024. 795 funds tracked by Wall St. Rank hold GPN as of Q1 2026.

  • Invenomic Capital Management held 914,505 shares of Global Payments worth $61.5M as of Q1 2026.
  • Invenomic Capital Management bought 117,009 Global Payments shares in Q1 2026, an estimated $8.63M.
  • Global Payments made up 2.82% of Invenomic Capital Management's portfolio in Q1 2026, its #3 holding.
  • Invenomic Capital Management first reported a position in Global Payments in Q1 2023 and has held it in 13 quarters since.
  • Invenomic Capital Management's Global Payments position peaked at $69.9M in Q3 2024.
  • 795 funds tracked by Wall St. Rank held Global Payments as of Q1 2026.

Based on Invenomic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.